Binge eating disorder

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Retrieved on: 
월요일, 10월 3, 2022
Psilocybin, PTSD, GLOBE, Tic disorder, Phrase, News, Risk, Binge eating disorder, Psychotherapy, PCT, THE, Liver, CSE, Pain, Â, Patent, World Intellectual Property Organization, WIPO, University, Therapy, Fibromyalgia, Safety, Chronic pain, IP, ID, Patient, IV, THIS, OCD, Depression, Pharmaceutical industry, Risk management, Operation Web Tryp, Company

KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO) published their international patent application (PCT/IB2022/052347) covering the intravenous administration of psilocybin and psilocin. The PCT application, titled “Improved Methods For The Use of Psychedelics” expands and strengthens the IP related to the Company’s development of TRP-8803, an IV formulation of psilocin, which will be administered in conjunction with psychotherapy.

Key Points: 
  • Psilocybin is a pro-drug which needs to be converted to psilocin, the active molecule that crosses the blood brain barrier and induces the psychedelic state.
  • These factors contribute to variable blood levels of psilocin, which can be either too low or too high.
  • Conversely, should the patient experience a side effect, the clinician can terminate administration of the drug, an option not available with oral administration.
  • Orally administered psychedelics have been widely introduced for use in treating depression, PTSD, OCD and other conditions, including by Tryp Therapeutics and its TRP-8802 programs.

Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

Retrieved on: 
월요일, 9월 26, 2022
Psilocybin, University, Risk, Safety, Memory, Psychotherapy, THE, Company, Fibromyalgia, News, Therapy, IP, Patient, Lists of diseases, Phrase, CSE, Binge eating disorder, Sleep, THIS, GLOBE, Fatigue, Patent, Chronic pain, Intellectual property, Pharmaceutical industry, Risk management, Operation Web Tryp

One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Companys development of TRP-8803.

Key Points: 
  • One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Companys development of TRP-8803.
  • We are methodically expanding our patent portfolio and remain committed to developing a combined psychedelic and psychotherapy treatment for patients suffering the debilitating effects of conditions such as fibromyalgia and Binge Eating Disorder.
  • The clinical studies are expected to reinforce the positive preclinical results obtained by Tryp in an animal model of nociplastic pain.
  • Once issued, the new patent will provide Tryp with Intellectual Property Protection for fibromyalgia utilizing its psilocybin-based candidates.

Tryp Therapeutics Appoints Jim O’Neill as Chief Financial Officer

Retrieved on: 
월요일, 9월 19, 2022
Psilocybin, University, Risk, CFO, Safety, CPA, Chartered, THE, Company, Fibromyalgia, Acquisition, Growth, News, Therapy, Patient, Phrase, CEO, CSE, Option, Binge eating disorder, Wilfrid Laurier University, THIS, GLOBE, Chronic pain, Pharmaceutical industry, Security (finance), Risk management, Financial adviser, Operation Web Tryp

KELOWNA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim ONeill as its Chief Financial Officer.

Key Points: 
  • KELOWNA, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim ONeill as its Chief Financial Officer.
  • The appointment of Mr. ONeill follows the planned transition of Sid Taubenfeld from interim Chief Financial Officer, to his current role as Chief Operating Officer.
  • Most recently, Mr. ONeill founded and served as president of ONeill & ONeill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies as well as private businesses.
  • Mr. ONeill also previously served as chief financial officer for various public and private companies with responsibilities including cash flow management, fundraising, financing, investment analysis, and evaluating potential merger and acquisition opportunities.

Discovery Behavioral Health Partners with MyClearStep To Enhance Remote Treatment of Eating Disorders

Retrieved on: 
목요일, 9월 15, 2022
Hospital, OSFED, Time, COVID-19, Blood pressure, TMS, Psychiatry, Conditional sentence, Virtual, Eating disorder, Partnership, Immunity, Purging disorder, Patient, Mental health, Addiction medicine, Big data, Happiness, Duke University, Technology, Lists of diseases, Binge eating disorder, Artificial intelligence, Behavior, Silicon, AI, ARFID, DBH, Disease, Medical device, Discovery

LOS ANGELES, Sept. 15, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc., an expanding network of evidence-based mental health, has partnered with MyClearStep, the leading remote patient solution by AI, to provide a new innovation in eating disorder recovery.

Key Points: 
  • LOS ANGELES, Sept. 15, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc., an expanding network of evidence-based mental health, has partnered with MyClearStep, the leading remote patient solution by AI, to provide a new innovation in eating disorder recovery.
  • Discovery Behavioral Health's Virtual IOP and Virtual PHP programs include treatment for eating disorders such as anorexia, bulimia, avoidant/restrictive food intake disorder (ARFID), other specified feeding and eating disorder (OSFED) and binge eating disorder.
  • Available for children, adolescents and adults in 37 states, all virtual services are confidential, secure and supervised by a team of experienced professionals who provide the same evidence-based treatment that Discovery Behavioral Health provides onsite in their treatment centers.
  • That's why Discovery Behavioral Health has made evidence-based, outcome driven healthcare accessible and affordable since inception.

Tryp Therapeutics Retains IMS Investor Relations

Retrieved on: 
화요일, 9월 13, 2022
Psilocybin, University, Risk, Safety, Wall Street, THE, Company, Fibromyalgia, Wall, News, Therapy, Patient, Phrase, IMS, CSE, Lists of diseases, Binge eating disorder, Drug development, THIS, GLOBE, Chronic pain, Pharmaceutical industry, Risk management, Operation Web Tryp

KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the retention of IMS Investor Relations (IMS) effective August 15, 2022.

Key Points: 
  • KELOWNA, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics , Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the retention of IMS Investor Relations (IMS) effective August 15, 2022.
  • IMS Investor Relations is a well-regarded firm, and we look forward to working with them to ensure that we are proactively and productively communicating our progress to Wall Street.
  • John Nesbett, Founder and President of IMS Investor Relations, commented, Tryp Therapeutics is at an exciting time in their development as they continue to progress through the clinical trial process and file patents for their potentially revolutionary IP.
  • IMS will work closely with Tryp management to develop and deploy a strategic capital markets program.

Monte Nido & Affiliates to Open their first Residential Eating Disorder Program in Cherry Hill, NJ

Retrieved on: 
화요일, 8월 23, 2022
Mortality, Clementine, Anorexia nervosa, Program, Doctor of Philosophy, Purging disorder, Joint Commission, Exercise addiction, Diagnosis, Adolescence, Rosewood Center, Eating disorder, Binge eating disorder, MS, LMHC, Network affiliate, Lists of diseases, Medicine

CHERRY HILL, N.J., Aug. 23, 2022 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center in Cherry Hill, New Jersey. Opening in late 2022, Clementine Cherry Hill will provide care for adolescents of all genders with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction. Clementine Cherry Hill will be the company's first program in New Jersey as it expands to its 15th state.

Key Points: 
  • CHERRY HILL, N.J., Aug. 23, 2022 /PRNewswire/ -- Monte Nido& Affiliates , one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center inCherry Hill, New Jersey.
  • Clementine Cherry Hill will be the company's first program in New Jersey as it expands to its 15th state.
  • Monte Nido& Affiliates is one of the country's largest and leading eating disorder platforms, offering inpatient, residential, and day treatment programs for eating disorders.
  • Founded in 1996,Monte Nido& Affiliates currently operates programs in fourteen states, with residential programs being Joint Commission accredited.Monte Nido& Affiliates includes five distinct eating disorder program brands:Monte Nido, Walden Behavioral Care, Rosewood Centers,Oliver-Pyatt Centers, and Clementine.

SHORT WAVE PHARMA SIGNS CLINICAL TRIAL AGREEMENT WITH THE SHEBA RESEARCH FUND AND THE SHEBA CENTER FOR EATING DISORDERS

Retrieved on: 
월요일, 8월 15, 2022
Death, Purging disorder, Movement, Anorexia nervosa, Risk, Chronic pain, Trial, Fund, Lists of diseases, Population, Shortwave broadband antenna, Incidence, Disability, Eating disorder, Suicide, Drama, Clinical trial, Method, Psilocybin, The Company, Patient, Company, Program, Ministry, Health care, Safety, Drug development, Neurodegeneration, Binge eating disorder, Physician, Conditional sentence, API, Agreement, Social, Shortwave radio, The Trial, Metabolism, Pharmaceutical industry, Residential care, Health, Research

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.

Key Points: 
  • The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
  • Anorexia nervosa is a life-threatening disease and a severe eating disorder that affects about 0.5-1% of the population.
  • Shortwave's leadership team combines years of experience in drug development and clinical research, accelerated regulatory pathways and pharmaceutical industry expertise.
  • As Israel's top facility for treating eating disorders, it strives to address the need for safe and effective novel treatments.

Idorsia announces financial results for the first half 2022 – reaching commercial stage

Retrieved on: 
화요일, 7월 26, 2022
TST, OLE, Health care, Multiple sclerosis, Awareness, Insomnia, MHRA, Medication, Brain, Ageing, Royal commission, Incidence, Polysomnography, CNS, Adult, US, Safety, Pediatrics, Binge eating disorder, Product, Policy, European Commission, Review, Cerebral vasospasm, Neurosurgery, Fabry disease, Patient, Pharmacokinetics, Hypertension, Blood pressure, ASAH, CHF, Medical device, Pharmaceutical industry, EU

Based on the estimated incidence of aSAH in Japan, approximately 10%of aSAH patients were treated with PIVLAZ in June 2022.

Key Points: 
  • Based on the estimated incidence of aSAH in Japan, approximately 10%of aSAH patients were treated with PIVLAZ in June 2022.
  • Daridorexant was approved by the US FDA in January 2022 and by the European Commission in April 2022.
  • Idorsia will also make the detailed results of the Phase 3 study available through scientific presentations and peer-reviewed publications.
  • The study is expected to conclude by the end of 2022, reporting results in the first quarter of 2023.

Arise Raises Over $4 Million to Build Inclusive Eating Disorder Treatment and Mental Health Support

Retrieved on: 
월요일, 7월 11, 2022
People, Anxiety, BIPOC, Health, Language, Greycroft, Solution, Microdeletion syndrome, COVID-19, Purging disorder, PTSD, Man, Medicaid, Eating disorder, Body image, Mental health, Personality disorder, Depression, Binge eating disorder, MPH, NEW, Lists of diseases, Trauma, ARFID, Food, Opioid use disorder, Coffee, Health insurance, City block, MD

NEW YORK, July 11, 2022 /PRNewswire/ -- Arise, the digital healthcare company enabling comprehensive care for eating disorders, mental health, and long-term healing, has launched today after raising over $4 million in a seed funding round. Arise is building a virtual-first care model to reach and engage more of the 30 million Americans who will experience an eating disorder in their lifetime — 80-90% of whom will not get care today. The round was led by Greycroft and BBG Ventures with participation from Wireframe Ventures, Cityblock co-founder Iyah Romm (he/him) and Sonder Health founder Sylvia Romm, MD, MPH (she/her), and PatientPing founder Jay Desai (he/him), among others.

Key Points: 
  • Arise is building a virtual-first care model to reach and engage more of the 30 million Americans who will experience an eating disorder in their lifetime 80-90% of whom will not get care today.
  • Arise will bring integrated community and clinical care to people living with disordered eating and eating disorders, which are a category of conditions that can show up in different ways for people including binge eating disorder, bulimia, anorexia, rumination disorder, avoidant or restrictive food intake disorder (ARFID), and other conditions.
  • Stigma makes it difficult for people to identify their eating disorder and this is magnified when your families and communities don't have language to describe, let alone identify, the eating disorder.
  • Arise launches at a time when eating disorders, which are the second deadliest behavioral health condition after opioid use disorder, are sharply increasing.

Monte Nido & Affiliates to Expand Access to Adolescent Eating Disorder Treatment in California with New Orange County Location

Retrieved on: 
금요일, 7월 8, 2022
Linda, Binge eating disorder, MS, Adolescence, Mortality, Joint Commission, Purging disorder, LMHC, Network affiliate, Anorexia nervosa, Eating disorder, Clementine, Doctor of Philosophy, Lists of diseases, Program, Rosewood Center, Citrus, Medicine, Casino

YORBA LINDA, Calif., July 8, 2022 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center in Yorba Linda, California. Opening late 2022, Clementine Orange County will provide care for adolescents with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction. Marking the second Clementine residential treatment program in California, Clementine Orange County will be the first to treat adolescents of all genders.

Key Points: 
  • Opening late 2022, Clementine Orange County will provide care for adolescents with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction.
  • Marking the second Clementine residential treatment program in California, Clementine Orange County will be the first to treat adolescents of all genders.
  • Today, there are six Monte Nido & Affiliates programs throughout California, and Clementine Orange County will be its seventh.
  • Monte Nido& Affiliates is one of the country's largest and leading eating disorder platforms, offering inpatient, residential, and day treatment programs for eating disorders.